Prot #CX-839-005: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Project: Research project

Project Details

StatusActive
Effective start/end date9/7/189/7/21

Funding

  • Calithera Biosciences, Inc. (Prot #CX-839-005)